PTC Therapeutics (PTCT) Misses Q4 EPS by 6c

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.85), $0.06 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $213 million versus the consensus estimate of $213.45 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• Johnson Outdoors names Asad Rahman as new CFO effective June 30
• Allegro MicroSystems (ALGM) PT Raised to $70 at TD Cowen: 'Secular + Cyclical Growth Combo'